- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
When used by persons who are hyperactive, struggle with concentration, or are easily distracted, atomoxetine acts on the brain to improve focus and reduce agitation. This drug may be utilized as a component of a therapy plan that includes social, educational, and psychological support.
To improve concentration and reduce impulsivity and hyperactivity in children and adults with ADHD, atomoxetine is used as a component of a comprehensive treatment plan. Selective norepinephrine reuptake inhibitors are a group of drugs that includes atomoxetine.
Norepinephrine is a naturally occurring chemical in the brain that regulates behavior. It increases norepinephrine levels in order to work.
Atomoxetine is available as a pill to be swallowed. In most cases, it is taken once daily in the morning or twice daily in the morning and late afternoon or early evening. You can take atomoxetine with or without food. Take atomoxetine every day at around the same time(s). Pay close attention to the instructions on the prescription label.
Atomoxetine (depending on the dose depending on the dose improved accuracy sustained attention in the v SD and v ITI tasks as well as impulsivity, compulsivity, and cognitive rigidity behaviors. It also enhanced spatial reference memory in the RAM. This mechanism is stopped by the chemical atomoxetine.
As a result, the brain's active noradrenaline levels rise. Noradrenaline levels that are higher in the brain contribute to a person's increased alertness and readiness for action. They perceive an improvement in their wellbeing and a rise in their vitality.
The Global atomoxetine market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
As part of an all-encompassing treatment plan, DRLS Atom aid is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adults aged 6 and older.
A professional in the management of ADHD, such as a pediatrician, child/adolescent psychiatrist, or psychiatrist, must begin treatment. The ICD guidelines or the most recent DSM criteria should be used to make the diagnosis.
The presence of ADHD symptoms in adults that existed in childhood should be verified. Atom aid should not be started when the confirmation of childhood ADHD symptoms is doubtful because third-party corroboration is preferred. ADHD cannot be diagnosed based alone on the presence of one or more symptoms.
Leading Indian pharmaceutical business Aurobindo Pharma Ltd. creates a variety of generic pharmaceutical goods. Their broad range of products includes Atomoxetine, an active component used in the drug Strattera to treat attention deficit hyperactivity disorder (ADHD).
A selective norepinephrine reuptake inhibitor (SNRI), atomoxetine helps people with ADHD improve their attention span, impulsive control, and hyperactivity by regulating the levels of certain substances in the brain.
It is a non-stimulant drug, offering it an alternate choice for people who might not tolerate or respond well to stimulant drugs frequently used to treat ADHD. Atomoxetine is produced by Aurobindo Pharma Ltd. in a variety of dose formulations to suit the needs and preferences of diverse patients.
They create oral capsules with different strengths ranging from 10 mg to 100 mg of Atomoxetine, which is what they manufacture. For simple administration and identification, the capsules are frequently color-coded and stamped with dose strength information.
To guarantee efficacy, safety, and consistency, Aurobindo Pharma Ltd. makes sure that its Atomoxetine product complies with strict quality requirements. GMP compliance, stringent quality control procedures, and regulatory standards established by international health authorities are all part of the production process.
The company's manufacturing facilities are outfitted with cutting-edge infrastructure and cutting-edge technology to create pharmaceutical items of the highest caliber. They work with a group of qualified experts who have received training in pharmaceutical manufacturing procedures and who follow stringent quality control procedures at every stage of production.
Throughout the production process, Aurobindo Pharma Ltd. places a high priority on patient safety and product quality. In order to improve the formulation and guarantee bioequivalence to the reference product, they carry out substantial research and development.
To guarantee equal therapeutic benefits, bioequivalence studies compare the pharmacokinetic characteristics of the branded medicine with the generic equivalent. To further ensure the identity, potency, purity, and dissolving characteristics of their Atomoxetine product, Aurobindo Pharma Ltd. also maintains a strong quality assurance system that regularly includes testing of raw materials, in-process inspections, and final product testing.
These tests are done in specialized labs with approved analytical techniques. To further assure correct handling and storage of the Atomoxetine product and to give clear instructions, the firm adheres to stringent packaging and labeling standards.
One of the top pharmaceutical firms in the world, Teva Pharmaceutical Industries Ltd., produces a variety of branded and generic drugs. Teva produces Atomoxetine, a drug principally used to treat attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults, as part of their diverse product line.
FDA-approved atomoxetine, sold under the trade name Teva-Atomoxetine, is primarily used to treat attention deficit hyperactivity disorder (ADHD).
It functions by raising the levels of norepinephrine, a neurotransmitter, in the brain and is a member of the pharmacological class known as selective norepinephrine reuptake inhibitors (SNRIs).
Teva-Atomoxetine is available in oral capsule form and comes in a range of strengths, including 10 mg, 18 mg, 25 mg, 40 mg, and 60 mg. Depending on the patient's age, weight, and the severity of their symptoms, a healthcare provider may recommend a different dose than what is shown on the label.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in the Industry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.